To compare costs between treatment strategies employed prior to and after prostate-specificmembrane antigen positron emission tomography/computed tomography (PSMA PET/CT) via theBrazilian Unified Health Care System and their impact on the therapeutic management ofbiochemical recurrence of prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.